Amyris, Inc. (AMRS)
Market Cap | 577.95M |
Revenue (ttm) | 258.82M |
Net Income (ttm) | -341.15M |
Shares Out | 363.49M |
EPS (ttm) | -1.21 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 7,110 |
Open | 1.55 |
Previous Close | 1.53 |
Day's Range | 1.52 - 1.59 |
52-Week Range | 1.25 - 5.31 |
Beta | 1.04 |
Analysts | Buy |
Price Target | 7.16 (+350.31%) |
Earnings Date | Mar 7, 2023 |
About AMRS
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company ... [Read more]
Financial Performance
In 2021, Amyris's revenue was $341.82 million, an increase of 97.43% compared to the previous year's $173.14 million. Losses were -$270.46 million, -29.26% less than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AMRS stock is "Buy." The 12-month stock price forecast is $7.16, which is an increase of 350.31% from the latest price.
News

AMYRIS LAUNCHES 4U BY TIA™ HAIRCARE LINE EXCLUSIVELY AT WALMART
EMERYVILLE, Calif. , Jan. 30, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

AMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE
EMERYVILLE, Calif. , Jan. 4, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

AMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT
EMERYVILLE, Calif. , Dec. 29, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION
EMERYVILLE, Calif., Dec. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

AMYRIS CONSUMER BRANDS DELIVER 80% CYBER MONDAY LIKE-FOR-LIKE GROWTH
EMERYVILLE, Calif. , Nov. 30, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

Amyris, Inc. (AMRS) Reports Q3 Loss, Misses Revenue Estimates
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -109.52% and 36.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AMYRIS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Sixth consecutive quarter of record consumer revenue – Consumer revenue of $46.6 million increased 98% compared to Q3 2021 Record core revenue of $71.1 million grew 49% compared to the prior year quar...

AMYRIS TO HOST THIRD QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 8
EMERYVILLE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

Amyris and World Wildlife Fund Announce Partnership to Protect Biodiversity
EMERYVILLE, Calif. , Oct. 25, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

AMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDS
EMERYVILLE, Calif. , Oct. 24, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

Amyris Brands Expanding in UK and Europe. Executing on continued accelerated growth and lower costs
EMERYVILLE, Calif. , Oct. 11, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Synthetic biology maker Amyris owns a 60% global market share for a product that's increasingly used in personal care products. Will it notch a profit in 2024?

AMYRIS TO PARTICIPATE AT SEPTEMBER INVESTOR CONFERENCES
EMERYVILLE, Calif. , Sept. 7, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

AMYRIS PUBLISHES SECOND ANNUAL ESG REPORT
EMERYVILLE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amyris, Inc.
Wilmington, Delaware--(Newsfile Corp. - August 9, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Amyris, Inc. (NASDAQ: AMRS) on behalf of stockhold...

Amyris, Inc. (AMRS) Reports Q2 Loss, Lags Revenue Estimates
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -50% and 20.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AMYRIS, INC. REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
Record consumer revenue of $43 million increased 108% compared to Q2 2021 Ingredients sold out in first half with $15 million backlog to be supplied in H2 Cost actions and price increases to deliver $...

AMYRIS TO PARTICIPATE AT THE UBS GENOMICS 2.0 AND MEDTECH INNOVATIONS SUMMIT
EMERYVILLE, Calif. , Aug. 3, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

AMYRIS TO HOST SECOND QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 9
EMERYVILLE, Calif. , July 28, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

AMYRIS BARRA BONITA FERMENTATION PLANT BEGINS INDUSTRIAL PRODUCTION
EMERYVILLE, Calif. , June 23, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

AMYRIS TO PARTICIPATE AT THE OPPENHEIMER 22nd ANNUAL CONSUMER CONFERENCE
EMERYVILLE, Calif. , June 7, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

AMYRIS PARTICIPATES IN INVESTOR CONFERENCES ON MAY 23, 24 AND 25, 2022
EMERYVILLE, Calif. , May 23, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

AMYRIS TO PARTICIPATE AT MAY INVESTOR CONFERENCES
EMERYVILLE, Calif. , May 23, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

Amyris (AMRS) Earnings and Revenues Lag Estimates in Q1
Amyris (AMRS) sees strong revenues in its consumer segment in Q1 driven by growth of its legacy brands and strong contribution from new brands.